PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.49%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-24.67%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.97%
Operating expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-17.97%
Total costs reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.31%
EBITDA change of 18.31% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Income change of 17.97% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
184.62%
Other expenses growth while Biotechnology reduces costs. Peter Lynch would examine differences.
18.43%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.43%
Income change of 18.43% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
58.16%
EPS change of 58.16% versus flat Biotechnology. Walter Schloss would verify quality.
58.16%
Diluted EPS change of 58.16% versus flat Biotechnology. Walter Schloss would verify quality.
96.23%
Share count reduction below 50% of Biotechnology median of 0.18%. Jim Chanos would check for issues.
96.23%
Diluted share reduction below 50% of Biotechnology median of 0.19%. Jim Chanos would check for issues.